|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide (KLH conjugated) to the 3rd cytoplasmic loop.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.7|
|Contains||0.01% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100-1:200|
OPA1-15207 detects TA1 from human samples.
OPA1-15207 has been successfully used in immunohistochemistry procedures. By immunohistochemistry, OPA1-15207 detects TA1 in formalin fixed, paraffin embedded human tissues.
The OPA1-15207 immunogen is a synthetic peptide (KLH conjugated) corresponding to the 3rd cytoplasmic loop.
TA1 has been reported in human brain, dorsal root ganglion, olfactory bulb, kidney, liver, lung, pancreas, prostate, skeletal muscle, small intestine, spleen, spinal cord, and stomach. An EST for TA1 has been identified from a human stomach cancer library.
G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
TA1; trace amine receptor 1
TA1; TAAR1; TAR1; TRAR1